These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3837819)

  • 1. Nutrition and renal osteodystrophy.
    Morii H; Nishizawa Y; Miki T; Ohnishi Y; Okui Y; Song G; Yukioka K; Kikunami K; Matsushita Y; Inoue T
    J Nutr Sci Vitaminol (Tokyo); 1985 Dec; 31 Suppl():S67-9. PubMed ID: 3837819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of renal osteodystrophy: correlation of bone histomorphometry and serum mineral and immunoreactive parathyroid hormone values before and after treatment with calcium carbonate or 25-hydroxycholecalciferol.
    Bordier PJ; Marie PJ; Arnaud CD
    Kidney Int Suppl; 1975 Jan; (2):102-12. PubMed ID: 1057669
    [No Abstract]   [Full Text] [Related]  

  • 3. [Long-term effects of a combination of 25-hydroxycholecalciferol and 1-alpha-hydroxycholecalciferol on osteodystrophy in chronic hemodialysis patients].
    Sebert JL; Marie A; Kuntz D; Marie P; Gueris J; Smadja A; Fournier A; Quichaud J
    Rev Rhum Mal Osteoartic; 1981; 48(7-9):535-41. PubMed ID: 7291931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of phosphate and other factors on the pathogenesis of renal osteodystrophy.
    Slatopolsky E; Rutherford WE; Martin K; Hruska K
    Adv Exp Med Biol; 1977; 81():467-75. PubMed ID: 899937
    [No Abstract]   [Full Text] [Related]  

  • 5. The treatment of renal osteodystrophy with 1-alpha-hydroxycholecalciferol.
    Junor BJ; Catto GR; Macleod M
    Calcif Tissue Res; 1977 May; 22 Suppl():112-6. PubMed ID: 912512
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of 1 alpha-hydroxycholecalciferol and 25-hydroxycholecalciferol in the treatment of renal osteodystrophy: greater effect of 25-hydroxycholecalciferol on bone mineralization.
    Fournier A; Bordier P; Gueris J; Sebert JL; Marie P; Ferrière C; Bedrossian J; DeLuca HF
    Kidney Int; 1979 Feb; 15(2):196-204. PubMed ID: 513484
    [No Abstract]   [Full Text] [Related]  

  • 7. 1alpha-Hydroxycholecalciferol in renal osteodystrophy.
    Pierides AM; Ellis HA; Ward MK; Simpson W; Kerr DN
    Calcif Tissue Res; 1977 May; 22 Suppl():105-11. PubMed ID: 912511
    [No Abstract]   [Full Text] [Related]  

  • 8. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
    Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
    Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
    [No Abstract]   [Full Text] [Related]  

  • 9. Bone histomorphometry of renal osteodystrophy in diabetic patients.
    Andress DL; Hercz G; Kopp JB; Endres DB; Norris KC; Coburn JW; Sherrard DJ
    J Bone Miner Res; 1987 Dec; 2(6):525-31. PubMed ID: 3455634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of renal osteodystrophy with 1alpha-hydroxycholecalciferol (1alpha-OH-D3) in conjunction with a high dialysate calcium.
    Winney RJ; Bone JM; Anderson TJ; Robson JS
    Calcif Tissue Res; 1977 May; 22 Suppl():94-100. PubMed ID: 912593
    [No Abstract]   [Full Text] [Related]  

  • 11. Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.
    Massry SG; Goldstein DA; Malluche HH
    Kidney Int; 1980 Oct; 18(4):409-18. PubMed ID: 7014981
    [No Abstract]   [Full Text] [Related]  

  • 12. Renal osteodystrophy in end-stage renal failure.
    Nortman DF; Coburn JW
    Postgrad Med; 1978 Nov; 64(5):123-30. PubMed ID: 714829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal osteodystrophy in dialysis patients: diagnosis and treatment.
    Fournier A; Oprisiu R; Hottelart C; Yverneau PH; Ghazali A; Atik A; Hedri H; Said S; Sechet A; Rasolombololona M; Abighanem O; Sarraj A; El Esper N; Moriniere P; Boudailliez B; Westeel PF; Achard JM; Pruna A
    Artif Organs; 1998 Jul; 22(7):530-57. PubMed ID: 9684690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of the use of newer analogs of vitamin D in the management of renal osteodystrophy.
    Coburn JW; Brickman AS
    Adv Exp Med Biol; 1978; 103():473-86. PubMed ID: 362852
    [No Abstract]   [Full Text] [Related]  

  • 15. [Immunoreactive parathyroid hormone, 25-hydroxycalciferol and bone histology in renal osteodystrophy (author's transl)].
    Offermann G; Schaefer K; Schulz A; Delling G
    Klin Wochenschr; 1976 Jul; 54(13):625-32. PubMed ID: 940299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the treatment of renal osteodystrophy in dialysis patients.
    Slatopolsky E
    Kidney Int Suppl; 1975 Jan; (2):253-5. PubMed ID: 169423
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of 1alpha-hydroxyvitamin D3 on calcium and mineral content of bone in renal osteodystrophy.
    Junor BJ; Catto GR
    Clin Endocrinol (Oxf); 1977 Dec; 7 Suppl():131s-138s. PubMed ID: 606411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of high dialysate calcium concentration on bone remodelling, serum biochemistry, and parathyroid hormone in patients with renal osteodystrophy.
    Drüeke T; Bordier PJ; Man NK; Jungers P; Marie P
    Kidney Int; 1977 Apr; 11(4):267-74. PubMed ID: 857076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alfacalcidol in the therapy of renal bone disease.
    Ritzerfeld M; Klasser M; Mann H
    Int J Clin Pharmacol Ther; 2001 Dec; 39(12):546-50. PubMed ID: 11770836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical picture, diagnosis and therapy of renal osteodystrophy].
    Bombor H
    Z Urol Nephrol; 1977 Aug; 70(8):603-7. PubMed ID: 335702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.